Sucampo Pharmaceuticals, Inc.

805 King Farm Boulevard, Suite 550

Rockville, MD 20850

 

 

June 20, 2017

 

VIA EDGAR

 

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attn: Jeffrey Gabor

 

Re:

Sucampo Pharmaceuticals, Inc.

Registration Statement on Form S-3

File No. 333-218641

 

 

Acceleration Request

Requested Date: Thursday, June 22, 2017

Requested Time: 4:00 P.M. Eastern Daylight Time

 

Dear Sir or Madam:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Sucampo Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) be accelerated so that the Registration Statement becomes effective on Thursday, June 22, 2017, at 4:00 p.m. (Washington, D.C. time), or as soon thereafter as may be practicable, or at such later time as the Company may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP, counsel to the Company, at (703) 456-8053, or in his absence, Madison Jones of Cooley LLP at (202) 728-7087.

 

 

	Sincerely,
	SUCAMPO PHARMACEUTICALS, INC.
	/s/ Peter Pfreundschuh
	By:    Peter Pfreundschuh
	Title: Chief Financial Officer

 

cc:		Alex Driggs, Sucampo Pharmaceuticals, Inc.
		Brian F. Leaf, Cooley LLP